The running injury that won't heal — what happens to recovery after 45
8 min read · Uplevel editorial
The Achilles flared in February. Not dramatically — not a rupture, not an acute event that stopped you mid-run. A soreness that developed over a week, that you rested for two weeks, that improved enough that you started running again, and that has been at roughly sixty percent of baseline ever since. That was four months ago. The IT band that announced itself in March of last year has not returned to silence despite three months of PT, foam rolling that has become its own daily ritual, and two cortisone injections that each produced two weeks of quiet followed by the return. The plantar fasciitis you cleared in three weeks at thirty-eight took eleven months this time. The hip flexor that won't release no matter what you've done to it — massage, dry needling, targeted strengthening — sits there like a structural protest that has no intention of resolving.
You know the PT is competent. The imaging shows nothing catastrophic — mild tendinopathy, some fascial thickening, nothing surgical. The advice you keep receiving, from sports medicine and from orthopedics, is technically accurate: these injuries take longer to heal as you get older. It's just that no one explains why, and the absence of a why makes the advice feel like a verdict rather than a roadmap.
The why is specific and, once understood, points toward interventions that the standard sports medicine conversation often doesn't reach.
The first mechanism involves GH secretion. Growth hormone plays a central role in tissue repair — it stimulates the production of IGF-1, which drives cell proliferation and protein synthesis in injured tissue, including tendon and ligament fibroblasts. The GH pulse that occurs in slow-wave sleep — the deep non-REM stages — is the primary delivery mechanism for this repair signal. By the time most people are in their forties, GH secretion has declined substantially from peak; by fifty, the decline is dramatic. This matters specifically for tendon and ligament recovery because these tissues have low inherent vascularity and slow metabolic turnover even in young people. They're already slow healers compared to muscle. When the GH pulse that drives their fibroblast activity has declined by fifty to seventy percent from its peak, the repair capacity of these tissues is operating at a fraction of its earlier potential. The same Achilles tendinopathy that resolved in three weeks at thirty-eight is now healing in the context of a dramatically reduced repair signal environment.
The second mechanism is the tendon's own blood supply — or rather its consistent lack of one. Tendons are among the least vascularized tissues in the body. The regions most prone to tendinopathy — the mid-substance of the Achilles, the lateral aspect of the IT band insertion at the knee, the proximal plantar fascia — are areas with particularly marginal blood supply. In young people, this marginal supply is adequate because the GH-axis repair signal is strong, turnover is rapid, and the tissue is remodeling consistently. In the midlife body with a reduced GH pulse, the limited vascularity becomes the limiting factor. Damaged tissue can't repair if it can't receive the cells and growth factors that repair requires, and it can't receive them if the blood vessel density is insufficient to deliver them. The tissue sits in a state of incomplete repair — not injured enough to produce a strong enough inflammatory signal for macrophage recruitment and active healing, not healthy enough to function fully, stuck at the damaged baseline.
Collagen remodeling is the third piece. Tendon is almost entirely collagen — type I collagen organized into hierarchical fiber structures that transmit enormous tensile loads. When tendon is overloaded or injured, the disorganized collagen and scar tissue that forms in the initial repair phase needs to be remodeled into properly organized fiber over months. This remodeling process depends on fibroblast activity, adequate mechanical loading signals, sufficient collagen precursors from dietary protein, and — again — GH-axis support. Cumulative microtrauma, which runners accumulate over years, can exceed remodeling capacity even without a single acute injury event. The tendon that has been slowly accumulating disorganized collagen since forty-two presents as tendinopathy — pain, stiffness, reduction in tissue quality — even without a specific precipitating event.
Sleep architecture compression compounds all of this. Slow-wave sleep — the stage where GH is secreted — compresses progressively through adulthood. The person who was sleeping eight hours and getting ninety minutes of slow-wave sleep at thirty is now sleeping six hours and getting forty-five minutes of slow-wave sleep at forty-eight, and both the voluntary sleep restriction and the age-related compression are contributing. Every slow-wave sleep deficit is a GH pulse that didn't happen, which is a repair signal the Achilles didn't receive. Across months of inadequate sleep, this compounds into a recovery deficit that runs faster than training load does.
The conventional sports medicine progression is logical and often appropriate: load management, eccentric strengthening protocols for tendinopathy, progressive return to activity, sometimes injections, sometimes imaging to rule out structural damage. For many people under forty-five, this progression works. The tissue responds. The injury resolves within a predictable timeframe. After forty-five, the same progression hits a ceiling in some people — the tissue isn't responding the way it used to, and the loading protocols that would normally stimulate remodeling aren't producing enough remodeling. The ceiling isn't always obvious until you've been doing everything right for three months and the improvement has stalled.
This is where regenerative approaches enter the conversation — specifically BPC-157 and TB-500 in the connective tissue context. BPC-157 has been researched primarily in animal models for its effects on tendon and ligament healing, with the central mechanism being angiogenesis: the compound appears to stimulate new blood vessel formation in poorly vascularized tissue, potentially providing the delivery infrastructure that stalled tendon repair needs. Multiple animal studies from the Zagreb research group have shown accelerated tendon-to-bone healing, improved tensile strength in repaired tendons, and accelerated muscle and ligament healing in various injury models. TB-500 — the synthetic peptide based on thymosin beta-4 — has been researched for cell migration to injury sites, actin cytoskeleton dynamics, and anti-inflammatory modulation. In combination, the two compounds are hypothesized to create a repair environment that addresses both the vascular delivery problem and the cellular migration component of tissue healing.
The honest framing about the evidence is important and the conversation around these compounds often skips it. The animal data is real and internally consistent, and it spans multiple injury models and decades of research. Human clinical trials are limited. The practitioners working in sports medicine integrative contexts who report favorable observations with BPC-157 and TB-500 are describing clinical experience, not controlled trial outcomes. The compounds are used by athletes and by people with chronic tendinopathy in ways that are ahead of the published human evidence. Your prescribing provider would be approaching this conversation with the animal data in hand, with whatever clinical observations they've accumulated, and with an honest acknowledgment that the human RCT confirmation hasn't arrived yet. That's the accurate framing. It's also not uniquely unusual — many interventions used in sports medicine operate in the space between compelling preclinical evidence and incomplete human trial data.
GH-axis support — through GH secretagogues that restore some of the slow-wave sleep GH pulse that has declined — addresses the upstream problem more directly. Sermorelin, Ipamorelin, CJC-1295 — these compounds stimulate the pituitary's own GH release rather than replacing GH directly, and their use in midlife for supporting tissue repair capacity is an area of active clinical interest. Restoring more of the GH pulse that drives fibroblast activity and IGF-1 production throughout the body addresses not just the injured tendon but the systemic recovery environment. Whether this is appropriate for a given person involves a full evaluation of GH-axis status and is a conversation for a prescribing provider.
Progressive loading remains the non-negotiable foundation. Tendons remodel in response to mechanical signal — specifically tensile load applied progressively. The eccentric loading protocols that sports medicine has developed for Achilles tendinopathy, patellar tendinopathy, and plantar fasciitis work because they provide this signal at the right magnitude and frequency. The problem after forty-five isn't that the signal is wrong; it's that the tissue's response to the signal has diminished. Supporting the response — through sleep, protein adequacy, and potentially through the peptide approaches described — may be what allows the loading protocol to produce the remodeling it was designed to produce.
What a slow-healing midlife running injury is signaling goes beyond the tendon. It's a window into whole-body recovery capacity — the GH-axis status, the sleep architecture, the collagen remodeling rate, the vascular health of marginal tissues. The Achilles that isn't healing is the most visible indication of a repair environment that is running below the level it needs to run at. Understanding that environment, and what's actually limiting it, is the question that the "recovery slows with age" explanation doesn't answer — but could.
Frequently asked